Drug shortage tied to cancer relapse in kids

A drug shortage led to cancer relapses in children and young adults in 2010, a real-world consequence of the ongoing problems of drugs in short supply in the USA, a hospital analysis showed for the first time Wednesday.

The finding suggests that substitutes for drugs in short supply can pose unsuspected health risks for patients with cancer. In this case, the generic drug, mechlorethamine, is part of a three-month chemotherapy treatment for Hodgkin’s lymphoma, a cancer of the lymph nodes and spleen that yearly afflicts perhaps 9,000 people, mostly teenagers nationwide.

Mechlorethamine is one of hundreds of drugs that have been in short supply in the past three years, according to the Food and Drug Administration. In the New England Journal of Medicine report led by Monika Metzger of St. Jude Children’s Research Hospital in Memphis, physicians show real harm tied to the shortage of the drug in 2010.

“The difference is just shocking. This had a real impact on patients,” Metzger says. “We thought the alternative was just as safe, of course, so it was a real surprise when we reviewed the data.”.

Explore more:  soccer pants

The shortage ended in October, according to manufacturer Lundbeck of Deerfield, Ill., Which recently sold the drug to another company. Manufacturing facility problems triggered the shortage in 2010, forcing physicians in the study to switch to a different generic drug regimen to battle Hodgkin’s lymphoma, one of the most treatable cancers.

Using hospital records to review the effects of the switch, study physicians compared cancer relapse rates among 181 patients treated with the original drug and 40 patients treated with a substitute after the shortage emerged. They found that while 25% of patients on the new regimen suffered cancer relapses, that happened to only 12% using the original drug, a statistically significant difference. None of the patients died, but ones whose cancer returned faced more toxic doses of cancer drugs and bone marrow transplants, tied to heart disease and more cancer later in life.

“This isn’t the most tightly controlled study ever conducted, but it raises real questions about safety with all these shortages,” says cancer expert Bruce Chabner of Massachusetts General Hospital in Boston. The American Society for Health-System Pharmacists lists 231 drugs as undergoing shortages, many of them vaccines and generic cancer drugs. “This is a ridiculous situation for the industry that leads the world in 21st-century meds but can’t provide 1960s drugs,” Chabner says. Hospitals and pharmacies are often forced to turn to a “gray market” in resold drugs to beat shortages, he says, wasting time and imposing higher costs on the health care system.

Explore more:  Jazz center Rudy Gobert out indefinitely with knee injury

“While the quality of drugs is a key focus, we remain extremely concerned about the current and potential shortages,” says Stephanie Yao of the Food And Drug Administration.

Last year, President Obama said prescription drug shortages, which had tripled from 2005 to 2010, “pose a serious and growing threat to public health.” He issued an executive order that called for reporting on shortages, speeding up review of steps needed to alleviate them and an investigation of hoarding by sellers. A “user fee” law reauthorized by Congress in July has encouraged the industry to notify the agency of shortages, Yao says. The FDA is tracking about 100 manufacturing-related drug shortages, down from 180 at this time last year.

“We did everything we could to minimize (the) disruption in supply,” says Lundbeck spokesman Matt Flesch, who says that starting in 2005, the company went through 20 firms in a failed attempt to hire a contractor to make the drug at a new facility. Lundbeck announced this month that it was selling the drug and nine others, including the leukemia drug, asparaginase, also undergoing a shortage, for $80 million to another drugmaker.

“The essential fact is that generic drugs are a low-profit industry, making it less attractive to drugmakers,” Chabner says, a reality he says is driven by federal drug cost reimbursement rates and pharmaceutical purchasing firm practices. “Eventually, we’re going to get into real trouble unless we solve this.”.

Related Posts

Terms & Conditions

Maybe you are interested soccer planet Stephen Borelli | USA TODAY aledo football Belmont takes down Lipscomb 87-62 Capello on the brink with Russian football in crisis…

Return & Refund Policy

Maybe you are interested Fed up: Will fliers’ anger finally bring passenger rights? Tatis, Jimenez in the big leagues from the start Hostess selling Wonder bread brand…

Cookies Policy

Maybe you are interested Southeastern Louisiana upsets Jacksonville State, 35-14 Packers DT Letroy Guion gets 4-game suspension Haas F1 eyeing U.S. Grand Prix as ‘home race’ in…

Disclaimer

Maybe you are interested big ten men’s soccer standings NFL says refs’ fist bump OK after Broncos TD Ukraine stifles air attacks but faces 200,000 Russians in…

Privacy Policy

Maybe you are interested Saddled with another loss, Packers seeking spark Indonesia says 10 nationals held hostage after ship hijacked 260 employees in Georgia’s largest school district…

Social

Maybe you are interested Golf Glance Flash flooding risks to spread to southern High Plains, mid-South and Northeast: Friday forecast blank soccer jerseys a&m football schedule YouTube…